Incurin

RSS

Estriol

Authorised
This medicine is authorised for use in the European Union.

Overview

Incurin is a veterinary medicine used for the treatment of hormone-dependent urinary incontinence resulting from sphincter mechanism incompetence (SMI) in ovariohysterectomised bitches (i.e. in dogs having had the ovaries and uterus removed surgically). Incurin contains the active substance estriol.

This EPAR was last updated on 24/02/2021

Authorisation details

Product details
Name
Incurin
Agency product number
EMEA/V/C/000047
Active substance
estriol
International non-proprietary name (INN) or common name
Estriol
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) codes
QG03CA04
Publication details
Marketing-authorisation holder
Intervet International BV
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
24/03/2000
Contact address
Intervet International B.V.
Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Product information

30/08/2014 Incurin - EMEA/V/C/000047 - IA/0006/G

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

The treatment of hormone-dependent urinary incontinence due to sphincter mechanism incompetence in ovariohysterectomised bitches.

Assessment history

How useful was this page?

Add your rating
Average
1 rating